EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) – Epidemiology Forecast to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world (IARC, 2016). Lung cancer is classified into three main types: non-small cell lung cancer (NSCLC), small cell lung cancer, and lung carcinoid tumor. NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers. Small cell lung cancer accounts for 10-15% of lung cancers, while carcinoid tumors are the rarest, occurring in fewer than 5% of lung cancers

In the 8MM, the diagnosed incident cases of NSCLC will increase from 791,563 cases in 2015 to 1,069,516 cases in 2025, at an Annual Growth Rate (AGR) of 3.51% per year. When examining the AGR by individual market, GlobalData forecasts that all markets will see an increase in the diagnosed incident cases of NSCLC during the forecast period. In 2015, there were 1,199,845 five-year diagnosed prevalent cases of NSCLC in the 8MM, which is expected to increase to 1,626,132 cases by 2025, at an AGR of 3.55%.

The relative survival of NSCLC varies by subtype, where adenocarcinoma has the highest survival, followed by squamous cell carcinoma, and large cell carcinoma. In the alternate forecast, due to the forecast increase in adenocarcinoma during 2015-2025, GlobalData epidemiologists expect an increase in relative survival and, consequently, an increase in the number of five-year diagnosed prevalent cases of NSCLC.

GlobalData epidemiologists also provided two forecasts to address potential changes in the epidemiology of NSCLC during the forecast period 2015-2025: one in which the historical distribution of histology subtypes are held constant throughout the forecast period, and an alternate forecast where the histology subtypes are forecast to change over time. The two forecasts provide different outlooks on the market depending on the baseline assumptions.

Scope

The Non-Small Cell Lung Cancer (NSCLC) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of NSCLC in these markets from 2015–2025. The incident cases are further segmented by sex and age, cancer stage at diagnosis (IA, IB, IIA, IIB, IIIA, IIIB, and IV), cancer histology subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other), and the presentation of the biomarker mutations by histology subtype (EGFR, KRAS, ALK, METExon 14, PIK3CA, BRAF V600E, and ROS1). The report also provides an alternate forecast scenario that takes into account potential changes in the diagnosed incident cases distribution by histology subtype.

The NSCLC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Epidemiology

2.1Disease Background

2.2Risk Factors and Comorbidities

2.3Global Trends

2.3.1Incidence

2.3.2Histological Subtypes

2.3.3Relative Survival

2.4Forecast Methodology

2.4.1Sources Used

2.4.2Forecast Assumptions and Methods – Base Forecast

2.4.3Forecast Assumptions and Methods – Alternate Forecast

2.4.4Sources Not Used

2.5Epidemiological Forecast for NSCLC (2015–2025) – Base Forecast

2.5.1Diagnosed Incident Cases of NSCLC

2.5.2Age-Specific Diagnosed Incident Cases of NSCLC

2.5.3Sex-Specific Diagnosed Incident Cases of NSCLC

2.5.4Age-Standardized Diagnosed Incidence of NSCLC

2.5.5Diagnosed Incident Cases of NSCLC by Clinical Stage at Diagnosis

2.5.6Diagnosed Incident Cases of NSCLC by Histology Subtype

2.5.7Mutations Among Diagnosed Incident Cases of Adenocarcinoma

2.5.8Mutations Among Diagnosed Incident Cases of Squamous Cell Carcinoma

2.5.9Mutations Among Diagnosed Incident Cases of NSCLC

2.5.10Five-Year Diagnosed Prevalent Cases of NSCLC

2.6Epidemiological Forecast for NSCLC (2015–2025) – Alternate Forecast

2.6.1Alternate Forecast – Diagnosed Incident Cases of NSCLC by Histology

2.6.2Alternate Forecast – Five-Year Diagnosed Prevalent Cases of NSCLC

2.7Discussion

2.7.1Epidemiological Forecast Insight

2.7.2Limitations of the Analysis

2.7.3Strengths of the Analysis

3Appendix

3.1Bibliography

3.2About the Authors

3.2.1Epidemiologists

3.2.2Reviewers

3.2.3Global Director of Therapy Analysis and Epidemiology

3.3About GlobalData

3.4About EpiCast

3.5Disclaimer

Table

Table 1: Risk Factors and Comorbidities for Lung Cancer

Table 2: Histological Subtype Distribution Among NSCLC

Table 3: 8MM, Relative Survival

Table 4: 8MM, Sources Used for Diagnosed Incidence of NSCLC

Table 5: 8MM, Sources Used for Cancer Stage at Diagnosis

Table 6: 8MM, Sources Used for NSCLC by Histological Subtypes

Table 7: US, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation

Table 8: 5EU, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation

Table 9: Japan, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation

Table 10: China (Urban), Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation

Table 11: 8MM, Sources Used for Relative Survival of NSCLC

Table 12: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015–2025

Table 13: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N (Row %), 2015

Table 14: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages =18 Years, N (Row %), 2015

Table 15: 8MM, Diagnosed Incident Cases of NSCLC by Clinical Stage at Diagnosis, Ages =18 Years, N, 2015

Table 16: 8MM, Diagnosed Incident Cases of NSCLC by Histological Subtypes, Ages =18 Years, N, 2015

Table 17: 8MM, Mutations Among Diagnosed Incident Cases of Adenocarcinoma, Both Sexes, Ages =18 Years, N, 2015

Table 18: 8MM, Mutations Among Diagnosed Incident Cases of Squamous Cell Carcinoma, Both Sexes, Ages =18 Years, N, 2015

Table 19: 8MM, Mutations Among Diagnosed Incident Cases of NSCLC, Both Sexes, N, Ages =18 Years, 2015

Table 20: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015–2025

Table 21: 8MM, Alternate Forecast, Diagnosed Incident Cases of NSCLC by Histology Subtypes, Ages =18 Years, N, 2015 and 2025

Table 22: 8MM, Alternate Forecast, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015–2025

Figures

Figure 1: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015–2025

Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N, 2015

Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages =18 Years, N, 2015

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of NSCLC, Ages =18 Years, N, 2015

Figure 5: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015–2025

Frequently asked questions

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) – Epidemiology Forecast to 2025 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) – Epidemiology Forecast to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) – Epidemiology Forecast to 2025 in real time.

  • Access a live EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) – Epidemiology Forecast to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.